The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net loss | -289,745 | -2,613,283 | -3,959,440 | -57,702,015 |
| Goodwill impairment charges | 0 | - | - | 56,675,210 |
| Shares issued as part of stock grants to vendors | 0 | - | - | 98,000 |
| Loss on issuance of financial instruments | -443,020 | -138,020 | - | - |
| Change in fair value of financial instruments | - | - | - | -6,176,097 |
| Original issue discount and interest accrued on quantum convertible note-Quantum Notes | - | 0 | - | - |
| Original issue discount and interest accrued on quantum convertible note | 0 | - | - | - |
| Loss on issuance of financial instruments | - | - | - | -2,513,234 |
| Change in fair value of financial instruments | 2,828,647 | -16,805 | -1,399,491 | - |
| Loss on extinguishment of loan | 0 | -126,125 | - | -645,979 |
| Deferred income tax assets and liabilities | 0 | 0 | - | -1,679,404 |
| Amortization of discount on note payable | 0 | 0 | 0 | 7,000 |
| Allowance for expected credit losses | 274,214 | 125,965 | 120,919 | 759,782 |
| Depreciation and amortization | 647,018 | 647,599 | 647,037 | 1,323,467 |
| Stock-based compensation | 0 | 371,930 | 392,106 | 896,537 |
| Amortization of right-of-use assets | 22,091 | 21,291 | 20,524 | 55,459 |
| Accounts receivable | 1,235,954 | -107,866 | 255,130 | 1,094,190 |
| Due from related party | 43,492 | -48,034 | -242,500 | -254,378 |
| Prepaids and other current assets | -27,517 | -119,955 | 83,168 | 202,245 |
| Accounts payable and accrued liabilities | 2,406,054 | 259,211 | 692,586 | -1,446,302 |
| Deferred revenue | -20,008 | 323,427 | 358,860 | -414,710 |
| Due to related parties | 0 | 0 | 0 | -210,755 |
| Operating lease liabilities | -18,586 | -17,546 | -16,778 | -92,870 |
| Right-of-use liabilities | - | 0 | - | - |
| Income tax payable | 0 | - | - | - |
| Net cash used in operating activities | -754,538 | -324,601 | -440,493 | -5,789,542 |
| Cash acquired from business combination- idoc | 0 | 0 | - | 29,123 |
| Purchases of fixed assets | 7,310 | 3,593 | 11,873 | 55,267 |
| Net cash used in investing activities | -7,310 | -3,593 | -11,873 | -26,144 |
| Repayment of notes payable-Exchange Note | - | - | - | 61,429 |
| Proceeds from convertible debt-Quantum Notes | - | - | - | 2,700,000 |
| Proceeds from convertible note-Quantum Convertible Note | 0 | - | - | - |
| Repayment of notes payable-Additional Bridge Notes | - | - | - | 52,680 |
| Proceeds from quantum convertible note | - | -509,366 | 509,366 | - |
| Proceeds from convertible note-September2024Convertible Note | 0 | - | - | 2,000,000 |
| Payments on september 2024 convertible note | - | - | - | 38,889 |
| Proceeds from reverse recapitalization with dhac | 0 | 0 | - | 1,323,362 |
| Repayment on advances of related party | 0 | 0 | - | 47,800 |
| Repayment on extension note | 0 | - | - | - |
| Repayment on additional bridge financing | 0 | - | - | - |
| Repayment on encompass purchase liability | -44 | 44 | - | - |
| Repayment on note payable | 668,092 | 0 | - | - |
| Payment to shareholder | 0 | 0 | 10,000 | - |
| Proceeds from convertible debt-Equity Line Of Credit | - | - | - | 760,000 |
| Proceeds from issuance of common stock | 450,550 | 0 | 90,634 | - |
| Repayment of notes payable-Extension Notes | - | - | - | 335,750 |
| Proceeds from notes issued during the period | 1,181,554 | 726,237 | - | - |
| Payments on factoring payable | 21,000 | 7,160 | 28,627 | 180,397 |
| Repayment of notes payable-Note Payable Issued August32023 | - | - | - | 38,200 |
| Payments due on acquisition purchase | 44 | - | - | - |
| Payments on due on acquisition purchase | - | - | - | 5,150 |
| Payments on finance lease liability | - | -25,000 | 25,000 | - |
| Payments on financing lease liability | 25,000 | - | - | - |
| Net cash provided by financing activities | 943,012 | 209,667 | 536,373 | 6,023,067 |
| Net change in cash | 181,164 | -118,527 | 84,007 | 207,381 |
| Cash and cash equivalents at beginning of period | 291,595 | 410,122 | 326,115 | - |
| Cash and cash equivalents at end of period | 472,759 | 291,595 | 410,122 | - |
VSEE HEALTH, INC. (VSEE)
VSEE HEALTH, INC. (VSEE)